FORXIGA® (dapagliflozin)

FORXIGA® is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1

References

  1. FORXIGA® (dapagliflozin) Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/27188 (Last accessed November 2017).
  2. IMS Health Longitudinal Patient Databases (Disease Analyzer), August 2016; IMS Health Total Patient Tracker, August 2016; IMS Health Longitudinal Patient Databases (CSD, LPD}, August 2016; IMS Health Longitudinal Patient Database (LRx}, March 2015.
  3. Wilding et al. Primary Care Diabetes 2017;11:437-444
  4. IMS Health Database, MIDAS August 2016.
  5. Rosenstock J et al. Diabetes Care 2015; 38: 376–383.
  6. QTERNTM (saxagliptin and dapagliflozin) Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/32750 (Last accessed November 2017).
  7. NICE guidelines NG28. Algorithm for blood glucose-lowering therapy in adults with type 2 diabetes. http://www.nice.org.uk/guidance/ng28/resources/algorithm-for-blood-glucose-lowering-therapy-in-adults-with-type-2-diabetes-2185604173 (Last accessed November 2017).
  8. DOF FOR/034/Nov2017
  9. Chen J, et al. Diabetes Ther 2010; 1: 57–92.
  10. Wright EM, et al. J Int Med 2007; 261: 32–43.
  11. Idris I and Donnelly R. Diabetes Obes Metab 2009; 11: 79–88.
  12. Bailey CJ, et al. Lancet 2010; 375: 2223–2233.
  13. Canagliflozin▼ Summary of Product Characteristics. https://www.medicines.org.uk/emc/medicine/28400 (Last accessed November 2017).
  14. Empagliflozin▼ Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/28973 (Last accessed November 2017).
  15. Ptaszynska A. et al. American Diabetes Association 72nd Scientific Sessions, June 8–12, 2012. Poster 1098-P.
  16. Bailey CJ, et al. BMC Med 2013; 11: 43.
  17. lnzucchi SE, et al. Diabetes Care 2015; 38: 140–149.
  18. Charbonnel B, et al. Diabetes Care 2006; 29: 2638–2643.
  19. Bosi E, et al. Diabetes Care 2007; 30: 890–895.
  20. Nauck MA, et al. Int J Clin Pract 2009; 63: 46–55.
  21. DeFronzo RA, et al. Diabetes Care 2009; 32: 1649–1655.
  22. Taskinen MR, et al. Diab Obes Metab 2011; 13: 65–74.
  23. Saxagliptin Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/22315 (Last accessed November 2017).
  24. Sitagliptin Summary of Product Characteristics. http://www.medicines org.uk/emc/medicine/19609 (Last accessed November 2017).
  25. Linagliptin Summary of Product Characteristics. http://www medicines org.uk/emc/medicine/25000 (last accessed November 2017).
  26. Alogliptin▼ Summary of Product Characteristics. http://www.medicines org.uk/emc/medicine/28513 (Last accessed November 2017).
  27. Vildagliptin Summary of Product Characteristics http://www medicines org.uk/emc/medicine/20734 (Last accessed November 2017).
  28. Rosenstock et al. Poster presented at the 14th Annual World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), Los Angeles, CA, USA; December 1-3, 2016
  29. The Clinical Practice Research Datalink. http://www.cprd.com/intro.asp (Last accessed November 2017).
  30. Williams T, et al. Ther Adv Drug Saf 2012; 3: 89–99.
  31. Wilding JP, et al. Presented at European Association for the Study of Diabetes (EASD) 2015, Stockholm. 14–18 September 2015. Poster 737-P.
  32. Wilding JP, et al. Diabetes Ther 2016; 7: 695–711.
  33. Matthaei S, et al. Diabetes Care 2015; 38: 365–372.
  34. Jabbour S, et al. Presented at the European Association for the Study of Diabetes (EASD) 2013, Barcelona. 23–27 September 2013. Poster 938.
  35. Wilding JP, et al. Ann Intern Med 2012; 156: 405–415.
  36. Wilding JP, et al. Diabetes Obes Metab 2014; 16: 124–136.
  37. Sexual and Urologic Problems of Diabetes. National Diabetes Information Clearinghouse. http://diabetes.niddk.nih.gov/dm/pubs/sup/ (Last accessed November 2017).
  38. Geerlings SE, et al. Diabetes Care 2000; 23: 744–749.
  39. Geerlings SE, et al. Int J Antimicrob Agents 2008; 31: S54–S57.
  40. Donders GG. Curr Infect Dis Rep 2002; 4: 536–539.
  41. US Food & Drug Administration Endocrinologic & Metabolic Advisory Committee. Background document dapagliflozin BM5-512148 NDA 202293. June/July 2011.
  42. Nauck M, et al. Diabetes Care 2011; 34: 2015–2022.
  43. List J et al. Circulation 2014; 130: A16682.
  44. Sonesson C et al. Presented at European Society of Cardiology (ESC). Barcelona, Spain. 30 August – 3 September, 2014. Poster 6094.
  45. EMDAC Background Document. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drug/endocrinologicaland metabolicdrugsadvisorycommittee/ucm378079.pdf (Last accessed November 2017).
  46. DECLARE-TIMI8. http://clinicaltrials.gov/ct2/show/NCT01730534 (Last accessed November 2017).
  47. Ljunggren O, et al. Diab Obes Metab 2012; 14: 990–999.
  48. Andersson Sundell K, et al. Presented at 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). Istanbul, Turkey. 5–7 November, 2015.
  49. Mills L, et al. J Diab Nurs 2014; 18: 8–12.
  50. FORXIGA® MIMS price. http://www.mims.co.uk/drugs/diabetes/oral-and-parenteral-hypoglycaemics/forxiga (Last accessed November 2017).

GB-9848

Date of preparation: November 2017.